Navigation Links
SRI International Researchers Present Promising New Therapeutic for the Treatment of Multiple Myeloma
Date:5/11/2010

MENLO PARK, Calif., May 11 /PRNewswire/ -- SRI International, an independent nonprofit research and development organization, announced today that researchers have developed an anti-angiogenic molecule SR16388 that has demonstrated preclinical antitumor activity against multiple myeloma (MM). The new research was recently presented at the annual meeting of the American Association for Cancer Research (AACR), held in Washington, D.C.

Multiple myeloma is a cancer of the immune system that affects plasma cells in bone marrow. It is the second most common blood-based malignancy (after lymphoma), affecting approximately 20,000 new patients each year.

"More effective treatment options for multiple myeloma are urgently needed and the SRI cancer drug discovery team is actively working on developing next-generation agents that may extend the lives of patients and lead to a cure," said Lidia Sambucetti, Ph.D., senior director of SRI's Center for Cancer Research.

SR16388 has been shown to have excellent oral bioavailability and a favorable safety profile.  In studies, it has shown to potently inhibit angiogenesis in lung and prostate cancers. Based on in vitro and in vivo preclinical data, SRI researchers believe that SR16388 has promise as a new therapeutic for the treatment of multiple myeloma. In the new work presented at AACR, researchers demonstrated that SR16388 inhibits the growth of multiple myeloma cells and experimental tumors. This agent is different from current multiple myeloma therapies in that it works by blocking the ability of cancer cells to survive and grow in hypoxic (low oxygen level) microenvironments that are typical of this malignancy. In part, the drug does this by inhibiting the development of new blood vessels that supply oxygen and nutrients to multiplying cancer cells. SR16388 is currently in late-stage preclinical development, which will prepare the agent for entry into human clinical trials.

About SRI's Biosciences Division

SRI's Biosciences Division carries out basic research, drug discovery, and drug development, and provides contract services. SRI has all of the resources necessary to take R&D from idea to IND®—from initial discovery to the start of human clinical trials—and specializes in cancer, immunology and inflammation, infectious disease, and neuroscience. SRI's product pipeline has yielded marketed drugs, therapeutics currently in clinical trials, and additional programs in earlier stages. In its CRO business, SRI has helped government and other clients and partners advance well over 100 drugs into patient testing. SRI is also working to create the next generation of technologies in areas such as diagnostics, drug delivery, medical devices, and systems biology.

About SRI International

Silicon Valley-based SRI International is one of the world's leading independent research and technology development organizations. SRI, which was founded by Stanford University as Stanford Research Institute in 1946 and became independent in 1970, has been meeting the strategic needs of clients and partners for more than 60 years. Perhaps best known for its invention of the computer mouse and interactive computing, SRI has also been responsible for major advances in networking and communications, robotics, drug discovery and development, advanced materials, atmospheric research, education research, economic development, national security, and more. The nonprofit institute performs sponsored research and development for government agencies, businesses, and foundations. SRI also licenses its technologies, forms strategic alliances, and creates spin-off companies. In 2009, SRI's consolidated revenues, including its wholly owned for-profit subsidiary, Sarnoff Corporation, were approximately $470 million.


'/>"/>
SOURCE SRI International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Medicomps Decipher Holter Monitor Provides Cardiac Reporting on the International Space Station
2. Novo Nordisk partners with international scientific community for Victoza(R) cardiovascular outcomes trial
3. Lexicon to Present at BIO International Convention
4. Phytomedics Inc. To Present at BIO 2010 International Convention
5. Systech International(R) Celebrates 25 Years of Innovating Packaging Technology Solutions
6. International Merchant Advisors to Develop Organic Science Branded Medical Marijuana Product Line
7. Winner Medical Participates in CMEF 2010, China International Medical Equipment Fair, in Shenzhen
8. International Merchant Advisors Completes All Stock Based Purchase of Medical Marijuana Company Organic Science, Inc.
9. Essilor Acquires FGX International, Becoming a Major Player in a New Fast-Growing Market
10. PricewaterhouseCoopers to Present First International Market Scorecard on Medical Technology Innovation at the 2010 International Medical Device Industry Compliance Congress
11. Bacterin International Introduces OsteoSelect(R) DBM Putty
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)... Ind. , Sept. 7, 2017  Zimmer Biomet ... in musculoskeletal healthcare, today announced that it will be ... Global Healthcare Conference at the Grand Hyatt hotel in ... 11, 2017 at 11:40 a.m. Eastern Time. ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
(Date:9/6/2017)... , Sept. 6, 2017 NeuroRx, a clinical ... Suicidal Ideation and Behavior (ASIB), has been granted Fast Track ... sequential therapy of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine ... a pivotal trial of this sequential therapy targeting patients who ... 1 ...
(Date:9/5/2017)... 5, 2017  Just 18 months after its February ... to announce the appointment of three new senior people ... Dominic Jones-Phillips and James Wright ... Tammy Wynne joins ... access writers. She has over ten years, experience in ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... ... to Moorwick”: the adventures of a young Scottish girl yearning to see the world. ... mother of five who used her time waiting for children to finish their extracurricular activities ... It was a way to give some meaning to the hours I waited for ...
(Date:9/20/2017)... ... 2017 , ... “Monique”: is the story of Monique, whose mother’s deteriorating ... published author, Colleen Crispi, has owned four beauty salons and written a book regarding ... estate and cooking. , “The doctor’s office was only three blocks away, and ...
(Date:9/19/2017)... ... September 19, 2017 , ... DeSola Group, a leading strategy, ... Flannery, to its strategic advisory and client development team. , In her ... clients across different industries to develop and implement market-justified strategies, modernize and transform ...
(Date:9/19/2017)... ... September 19, 2017 , ... Peter ... the President’s Malaria Initiative (PMI) Africa Indoor Residual Spraying (AIRS) Project , ... , The Innovation to Action Award, a USAID Catalyst Award, recognizes USAID ...
(Date:9/19/2017)... ... September 19, 2017 , ... CTNext , ... Innovation Awards (EIA), held this past Thursday night at The Space in Hamden. ... presented their innovative project ideas to a panel of judges for an opportunity ...
Breaking Medicine News(10 mins):